> No evidence exists that indicate sthat treatment with erythropoietin alters the metabolism of other medicinal products.Medicinal products that decrease erythropoiesis may decrease the response to SILAPO.Since CICLOSPORIN is bound by RBCs there is potential for a drug interaction. If SILAPO is given concomitantly with CICLOSPORIN, blood levels of CICLOSPORIN should be monitored and the dose of CICLOSPORIN adjusted as the haematocrit r ises.No evidence exists that indicates an interaction between SILAPO and G -CSF or GM -CSF with regard to haematological differentiation or proliferation of tumour biopsy specimens in vitro .In female adult patients with metastatic breast cancer, subcutaneous co -administration of 
40000IU/m
